Inogen (INGN) Income from Continuing Operations (2013 - 2026)
Inogen's (INGN) quarterly Income from Continuing Operations came in at 8324000.0 in Q1 2026, down 34.82% year-on-year from 12771465.21 in Q1 2025, and down 193.39% on a QoQ basis from 8913000.0 in Q4 2025.
Inogen (INGN) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Inogen (INGN) has 14 years of Income from Continuing Operations data on file, last reported at 8324000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 34.82% year-over-year to 8324000.0 in Q1 2026; TTM through Mar 2026 was 8857000.0, a 58.14% increase from a year earlier, with the FY2025 full-year figure at 6707000.0, up 77.31% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 8324000.0, down from 8913000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for INGN reached as high as 72460000.0 in Q4 2023 and fell as low as 56610000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 7753058.82 across 5 years, with a median of 6174000.0 in 2025.
- Across the five-year window, Income from Continuing Operations slumped 1841.8% in 2022 and soared 359.55% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 56610000.0 in 2022, then jumped by 228.0% to 72460000.0 in 2023, then tumbled by 104.74% to 3434000.0 in 2024, then surged by 359.55% to 8913000.0 in 2025, then plunged by 193.39% to 8324000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 8324000.0 in Q1 2026, 8913000.0 in Q4 2025, and 5294000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Inogen | 172.68 Mn | 62.51 Mn | 37.86 Mn | -8.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.32 Mn |
| Dec 31, 2025 | 8.91 Mn |
| Sep 30, 2025 | -5.29 Mn |
| Jun 30, 2025 | -4.15 Mn |
| Mar 31, 2025 | -6.17 Mn |
| Dec 31, 2024 | -3.43 Mn |
| Sep 30, 2024 | -5.96 Mn |
| Jun 30, 2024 | -5.59 Mn |
| Mar 31, 2024 | -14.58 Mn |
| Dec 31, 2023 | 72.46 Mn |
| Sep 30, 2023 | -45.72 Mn |
| Jun 30, 2023 | -9.83 Mn |
| Mar 31, 2023 | -20.35 Mn |
| Dec 31, 2022 | -56.61 Mn |
| Sep 30, 2022 | -9.51 Mn |
| Jun 30, 2022 | -3.44 Mn |
| Mar 31, 2022 | -14.21 Mn |
| Dec 31, 2021 | -22.88 Mn |
| Sep 30, 2021 | 12.17 Mn |
| Jun 30, 2021 | 5.10 Mn |